Clinical Trial Update: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating gemcitabine hydrochloride and eribulin mesylate in advanced or unresectable bladder, ureter, and urethral urothelial carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Urothelial Carcinoma
• Ureter Cancer
• Ureter Urothelial Carcinoma
• Urethral Cancer
• Urethral Urothelial Carcinoma

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-12-16